Rabeprazole + Rabeprazole
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Conditions
Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
Trial Timeline
Dec 1, 2011 → Feb 1, 2014
NCT ID
NCT01398410About Rabeprazole + Rabeprazole
Rabeprazole + Rabeprazole is a phase 2/3 stage product being developed by Eisai for Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin. The current trial status is completed. This product is registered under clinical trial identifier NCT01398410. Target conditions include Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01398410 | Phase 2/3 | Completed |
| NCT00787891 | Phase 3 | Completed |
Competing Products
20 competing products in Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin